Karen Huang, DO
Gastroenterology · Midland, MINPI 1952509911
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.1% of the total across 256 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by AbbVie at 30.2% of the total. Reporting peaked in 2022 at $897 and has fallen 66.9% since, to $297 in 2025.
Across 256 payments — averaging $15.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Pfizer$502
- Johnson & Johnson$418
- Gilead$364
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$307
- Takeda Pharmaceuticals U.S.A., Inc.$266
- plus $836 from 16 others
What the payments were for
- Food & beverage$3,74697%
- Education$1103%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 85 | $1,163 |
| Pfizer | 32 | $502 |
| Johnson & Johnson | 46 | $418 |
| Gilead | 22 | $364 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 18 | $307 |
| Takeda Pharmaceuticals U.S.A., Inc. | 17 | $266 |
| Madrigal Pharmaceuticals | 2 | $144 |
| QOL Medical, LLC | 3 | $136 |
| Intercept Pharmaceuticals, Inc. | 6 | $106 |
| Ironwood Pharmaceuticals, Inc | 4 | $84 |
| Merck | 5 | $84 |
| Ferring Pharmaceuticals Inc. | 3 | $57 |
| UCB, Inc. | 3 | $44 |
| Braintree Laboratories, Inc. | 2 | $36 |
| Daiichi Sankyo Inc. | 1 | $22 |
| Aimmune Therapeutics, Inc. | 1 | $20 |
| Shire North American Group Inc | 1 | $20 |
| Bristol Myers Squibb | 1 | $19 |
| Shionogi Inc | 1 | $19 |
| Sanofi | 1 | $18 |
| Boston Scientific | 1 | $14 |
| AstraZeneca | 1 | $13 |
How this compares
$3,856 in reported general payments places this provider in the 65th percentile of 497 gastroenterology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Entyvio PenVedolizumab | 14 | $85,957 |
| Humira PenAdalimumab | 12 | $78,752 |
| Xeljanz XrTofacitinib Citrate | 13 | $71,666 |
| XifaxanRifaximin | 18 | $50,218 |
| LinzessLinaclotide | 33 | $44,075 |
| Mesalamine | 33 | $27,090 |
| VemlidyTenofovir Alafenamide | 12 | $16,035 |
| Colestipol Hcl | 80 | $5,915 |
| Omeprazole | 183 | $5,527 |
| Pantoprazole Sodium | 317 | $5,061 |
| Sucralfate | 70 | $4,699 |
| Azathioprine | 42 | $3,745 |
| Balsalazide Disodium | 11 | $3,567 |
| Mesalamine ErMesalamine | 15 | $3,425 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 18 | $2,866 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $307 | $50,21818 claims |
| AbbVieLinzess | $1,163 | $44,07533 claims |
| GileadVemlidy | $364 | $16,03512 claims |
| Braintree Laboratories, Inc.Sutab | $36 | $2,86618 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 497 gastroenterology providers in Michigan.
Other gastroenterology in Midland
- Kimberly BrownDetroit$733K
- Dilip MoonkaDetroit$611K
- Philip SchoenfeldAnn Arbor$539K
- Michelle Muza-MoonsAnn Arbor$481K
- Partha NandiTroy$377K
- Bradford WhitmerSaint Clair Shores$206K
- Mohammed BarawiSt Clair Shores$193K
- Stuart GordonDetroit$178K
- Mohamad AlsibaeRoyal Oak$127K
- Allison SchulmanAnn Arbor$124K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.